Effect of Clentiazem (TA-3090) with Posttreatment on Neurologic and Histologic Disorders of Stroke-Prone Spontaneously Hypertensive Rats with History of Stroke
SUMMARYAfter stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) ora...
Gespeichert in:
| Veröffentlicht in: | Journal of cardiovascular pharmacology 1994-01, Vol.23 (1), p.166-166 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 166 |
|---|---|
| container_issue | 1 |
| container_start_page | 166 |
| container_title | Journal of cardiovascular pharmacology |
| container_volume | 23 |
| creator | Kikkawa, Kohei Murata, Sakae Kurosawa, Hideo Toriumi, Wataru Iwasaki, Hitoshi Nagao, Taku |
| description | SUMMARYAfter stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) orally twice daily (b.i.d.) for 28 days after the occurrence of stroke reduced neurologic symptoms and histologic changes of brain and kidney in a dose-dependent manner. Acute treatment with clentiazem (15 mg/kg, b.i.d.) administered immediately after stroke for 1 week not only almost completely abolished neurologic symptoms during treatment, but partially improved them even after treatment. Subacute treatment with clentiazem starting 10 days after stroke and continuing for 18 days also suppressed the neurologic signs. Both acute and subacute treatment improved cerebral histology. These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficialAfter stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) orally twice daily (b.i.d.) for 28 days after the occurrence of stroke reduced neurologic symptoms and histologic changes of brain and kidney in a dose-dependent manner. Acute treatment with clentiazem (15 mg/kg, b.i.d.) administered immediately after stroke for 1 week not only almost completely abolished neurologic symptoms during treatment, but partially improved them even after treatment. Subacute treatment with clentiazem starting 10 days after stroke and continuing for 18 days also suppressed the neurologic signs. Both acute and subacute treatment improved cerebral histology. These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficial. |
| doi_str_mv | 10.1097/00005344-199401000-00023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76420453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76420453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4343-8c3675468ab4d8b1a7e456de1d300940ec43e490391d4a477afeb6b1ed16973b3</originalsourceid><addsrcrecordid>eNp1UtFuFCEUJUZT19VPMOHBGH1AYWFg5rFZq9ukaRtbnwkzc8fFMsMKjJv1Z_zV0s64PklC4Oaecy45B4Qwox8YrdRHmlfBhSCsqgRluSJ5r_gTtGAF50Tk-1O0oExSshJCPkcvYvxBKROFkifoRBWMKU4X6M9Z10GTsO_w2sGQrPkNPX53e0o4reh7vLdpi699TCmASX1GYD_gSxiDd_67bbAZWryxMc3lJxt9aCHEB8WbFPwdkOvgB8A3Oz8kM4AfozvgzWEHIcEQ7S_AX02K06RHpXD4R36JnnXGRXg1n0v07fPZ7XpDLq6-nK9PL0gjuOCkbLhUhZClqUVb1swoEIVsgbWc0uwQZBiIivKKtcIIpUwHtawZtExWitd8id5Ourvgf44Qk-5tbMC56cVaSbGiIlu7ROUEbIKPMUCnd8H2Jhw0o_ohG_03G33MRj9mk6mv5xlj3UN7JM5h5P6buW9iY1wXzNDYeITxUvKyKDJMTLC9dyk7fefGPQS9BePSVv_vZ_B7cDOneQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76420453</pqid></control><display><type>article</type><title>Effect of Clentiazem (TA-3090) with Posttreatment on Neurologic and Histologic Disorders of Stroke-Prone Spontaneously Hypertensive Rats with History of Stroke</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Kikkawa, Kohei ; Murata, Sakae ; Kurosawa, Hideo ; Toriumi, Wataru ; Iwasaki, Hitoshi ; Nagao, Taku</creator><creatorcontrib>Kikkawa, Kohei ; Murata, Sakae ; Kurosawa, Hideo ; Toriumi, Wataru ; Iwasaki, Hitoshi ; Nagao, Taku</creatorcontrib><description>SUMMARYAfter stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) orally twice daily (b.i.d.) for 28 days after the occurrence of stroke reduced neurologic symptoms and histologic changes of brain and kidney in a dose-dependent manner. Acute treatment with clentiazem (15 mg/kg, b.i.d.) administered immediately after stroke for 1 week not only almost completely abolished neurologic symptoms during treatment, but partially improved them even after treatment. Subacute treatment with clentiazem starting 10 days after stroke and continuing for 18 days also suppressed the neurologic signs. Both acute and subacute treatment improved cerebral histology. These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficialAfter stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) orally twice daily (b.i.d.) for 28 days after the occurrence of stroke reduced neurologic symptoms and histologic changes of brain and kidney in a dose-dependent manner. Acute treatment with clentiazem (15 mg/kg, b.i.d.) administered immediately after stroke for 1 week not only almost completely abolished neurologic symptoms during treatment, but partially improved them even after treatment. Subacute treatment with clentiazem starting 10 days after stroke and continuing for 18 days also suppressed the neurologic signs. Both acute and subacute treatment improved cerebral histology. These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficial.</description><identifier>ISSN: 0160-2446</identifier><identifier>EISSN: 1533-4023</identifier><identifier>DOI: 10.1097/00005344-199401000-00023</identifier><identifier>PMID: 7511730</identifier><identifier>CODEN: JCPCDT</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott-Raven Publishers</publisher><subject>Administration, Oral ; Animals ; Antihypertensive Agents - pharmacology ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Blood Pressure - drug effects ; Body Weight - drug effects ; Brain - drug effects ; Brain - pathology ; Cardiovascular system ; Cerebrovascular Disorders - drug therapy ; Cerebrovascular Disorders - pathology ; Diltiazem - administration & dosage ; Diltiazem - analogs & derivatives ; Diltiazem - pharmacology ; Diltiazem - therapeutic use ; Dose-Response Relationship, Drug ; Heart Rate - drug effects ; Hypertension - drug therapy ; Kidney - drug effects ; Kidney - pathology ; Medical sciences ; Miscellaneous ; Nervous System - drug effects ; Pharmacology. Drug treatments ; Rats ; Rats, Inbred SHR ; Sodium, Dietary</subject><ispartof>Journal of cardiovascular pharmacology, 1994-01, Vol.23 (1), p.166-166</ispartof><rights>Lippincott-Raven Publishers.</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4343-8c3675468ab4d8b1a7e456de1d300940ec43e490391d4a477afeb6b1ed16973b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00005344-199401000-00023$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,776,780,4009,4594,27902,27903,27904,65209</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3863855$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7511730$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kikkawa, Kohei</creatorcontrib><creatorcontrib>Murata, Sakae</creatorcontrib><creatorcontrib>Kurosawa, Hideo</creatorcontrib><creatorcontrib>Toriumi, Wataru</creatorcontrib><creatorcontrib>Iwasaki, Hitoshi</creatorcontrib><creatorcontrib>Nagao, Taku</creatorcontrib><title>Effect of Clentiazem (TA-3090) with Posttreatment on Neurologic and Histologic Disorders of Stroke-Prone Spontaneously Hypertensive Rats with History of Stroke</title><title>Journal of cardiovascular pharmacology</title><addtitle>J Cardiovasc Pharmacol</addtitle><description>SUMMARYAfter stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) orally twice daily (b.i.d.) for 28 days after the occurrence of stroke reduced neurologic symptoms and histologic changes of brain and kidney in a dose-dependent manner. Acute treatment with clentiazem (15 mg/kg, b.i.d.) administered immediately after stroke for 1 week not only almost completely abolished neurologic symptoms during treatment, but partially improved them even after treatment. Subacute treatment with clentiazem starting 10 days after stroke and continuing for 18 days also suppressed the neurologic signs. Both acute and subacute treatment improved cerebral histology. These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficialAfter stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) orally twice daily (b.i.d.) for 28 days after the occurrence of stroke reduced neurologic symptoms and histologic changes of brain and kidney in a dose-dependent manner. Acute treatment with clentiazem (15 mg/kg, b.i.d.) administered immediately after stroke for 1 week not only almost completely abolished neurologic symptoms during treatment, but partially improved them even after treatment. Subacute treatment with clentiazem starting 10 days after stroke and continuing for 18 days also suppressed the neurologic signs. Both acute and subacute treatment improved cerebral histology. These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficial.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Body Weight - drug effects</subject><subject>Brain - drug effects</subject><subject>Brain - pathology</subject><subject>Cardiovascular system</subject><subject>Cerebrovascular Disorders - drug therapy</subject><subject>Cerebrovascular Disorders - pathology</subject><subject>Diltiazem - administration & dosage</subject><subject>Diltiazem - analogs & derivatives</subject><subject>Diltiazem - pharmacology</subject><subject>Diltiazem - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Heart Rate - drug effects</subject><subject>Hypertension - drug therapy</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Nervous System - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Inbred SHR</subject><subject>Sodium, Dietary</subject><issn>0160-2446</issn><issn>1533-4023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UtFuFCEUJUZT19VPMOHBGH1AYWFg5rFZq9ukaRtbnwkzc8fFMsMKjJv1Z_zV0s64PklC4Oaecy45B4Qwox8YrdRHmlfBhSCsqgRluSJ5r_gTtGAF50Tk-1O0oExSshJCPkcvYvxBKROFkifoRBWMKU4X6M9Z10GTsO_w2sGQrPkNPX53e0o4reh7vLdpi699TCmASX1GYD_gSxiDd_67bbAZWryxMc3lJxt9aCHEB8WbFPwdkOvgB8A3Oz8kM4AfozvgzWEHIcEQ7S_AX02K06RHpXD4R36JnnXGRXg1n0v07fPZ7XpDLq6-nK9PL0gjuOCkbLhUhZClqUVb1swoEIVsgbWc0uwQZBiIivKKtcIIpUwHtawZtExWitd8id5Ourvgf44Qk-5tbMC56cVaSbGiIlu7ROUEbIKPMUCnd8H2Jhw0o_ohG_03G33MRj9mk6mv5xlj3UN7JM5h5P6buW9iY1wXzNDYeITxUvKyKDJMTLC9dyk7fefGPQS9BePSVv_vZ_B7cDOneQ</recordid><startdate>199401</startdate><enddate>199401</enddate><creator>Kikkawa, Kohei</creator><creator>Murata, Sakae</creator><creator>Kurosawa, Hideo</creator><creator>Toriumi, Wataru</creator><creator>Iwasaki, Hitoshi</creator><creator>Nagao, Taku</creator><general>Lippincott-Raven Publishers</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199401</creationdate><title>Effect of Clentiazem (TA-3090) with Posttreatment on Neurologic and Histologic Disorders of Stroke-Prone Spontaneously Hypertensive Rats with History of Stroke</title><author>Kikkawa, Kohei ; Murata, Sakae ; Kurosawa, Hideo ; Toriumi, Wataru ; Iwasaki, Hitoshi ; Nagao, Taku</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4343-8c3675468ab4d8b1a7e456de1d300940ec43e490391d4a477afeb6b1ed16973b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Body Weight - drug effects</topic><topic>Brain - drug effects</topic><topic>Brain - pathology</topic><topic>Cardiovascular system</topic><topic>Cerebrovascular Disorders - drug therapy</topic><topic>Cerebrovascular Disorders - pathology</topic><topic>Diltiazem - administration & dosage</topic><topic>Diltiazem - analogs & derivatives</topic><topic>Diltiazem - pharmacology</topic><topic>Diltiazem - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Heart Rate - drug effects</topic><topic>Hypertension - drug therapy</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Nervous System - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Inbred SHR</topic><topic>Sodium, Dietary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kikkawa, Kohei</creatorcontrib><creatorcontrib>Murata, Sakae</creatorcontrib><creatorcontrib>Kurosawa, Hideo</creatorcontrib><creatorcontrib>Toriumi, Wataru</creatorcontrib><creatorcontrib>Iwasaki, Hitoshi</creatorcontrib><creatorcontrib>Nagao, Taku</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiovascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kikkawa, Kohei</au><au>Murata, Sakae</au><au>Kurosawa, Hideo</au><au>Toriumi, Wataru</au><au>Iwasaki, Hitoshi</au><au>Nagao, Taku</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Clentiazem (TA-3090) with Posttreatment on Neurologic and Histologic Disorders of Stroke-Prone Spontaneously Hypertensive Rats with History of Stroke</atitle><jtitle>Journal of cardiovascular pharmacology</jtitle><addtitle>J Cardiovasc Pharmacol</addtitle><date>1994-01</date><risdate>1994</risdate><volume>23</volume><issue>1</issue><spage>166</spage><epage>166</epage><pages>166-166</pages><issn>0160-2446</issn><eissn>1533-4023</eissn><coden>JCPCDT</coden><abstract>SUMMARYAfter stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) orally twice daily (b.i.d.) for 28 days after the occurrence of stroke reduced neurologic symptoms and histologic changes of brain and kidney in a dose-dependent manner. Acute treatment with clentiazem (15 mg/kg, b.i.d.) administered immediately after stroke for 1 week not only almost completely abolished neurologic symptoms during treatment, but partially improved them even after treatment. Subacute treatment with clentiazem starting 10 days after stroke and continuing for 18 days also suppressed the neurologic signs. Both acute and subacute treatment improved cerebral histology. These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficialAfter stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) orally twice daily (b.i.d.) for 28 days after the occurrence of stroke reduced neurologic symptoms and histologic changes of brain and kidney in a dose-dependent manner. Acute treatment with clentiazem (15 mg/kg, b.i.d.) administered immediately after stroke for 1 week not only almost completely abolished neurologic symptoms during treatment, but partially improved them even after treatment. Subacute treatment with clentiazem starting 10 days after stroke and continuing for 18 days also suppressed the neurologic signs. Both acute and subacute treatment improved cerebral histology. These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficial.</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>7511730</pmid><doi>10.1097/00005344-199401000-00023</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0160-2446 |
| ispartof | Journal of cardiovascular pharmacology, 1994-01, Vol.23 (1), p.166-166 |
| issn | 0160-2446 1533-4023 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76420453 |
| source | MEDLINE; Journals@Ovid LWW Legacy Archive; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Administration, Oral Animals Antihypertensive Agents - pharmacology Antihypertensive Agents - therapeutic use Biological and medical sciences Blood Pressure - drug effects Body Weight - drug effects Brain - drug effects Brain - pathology Cardiovascular system Cerebrovascular Disorders - drug therapy Cerebrovascular Disorders - pathology Diltiazem - administration & dosage Diltiazem - analogs & derivatives Diltiazem - pharmacology Diltiazem - therapeutic use Dose-Response Relationship, Drug Heart Rate - drug effects Hypertension - drug therapy Kidney - drug effects Kidney - pathology Medical sciences Miscellaneous Nervous System - drug effects Pharmacology. Drug treatments Rats Rats, Inbred SHR Sodium, Dietary |
| title | Effect of Clentiazem (TA-3090) with Posttreatment on Neurologic and Histologic Disorders of Stroke-Prone Spontaneously Hypertensive Rats with History of Stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T11%3A49%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Clentiazem%20(TA-3090)%20with%20Posttreatment%20on%20Neurologic%20and%20Histologic%20Disorders%20of%20Stroke-Prone%20Spontaneously%20Hypertensive%20Rats%20with%20History%20of%20Stroke&rft.jtitle=Journal%20of%20cardiovascular%20pharmacology&rft.au=Kikkawa,%20Kohei&rft.date=1994-01&rft.volume=23&rft.issue=1&rft.spage=166&rft.epage=166&rft.pages=166-166&rft.issn=0160-2446&rft.eissn=1533-4023&rft.coden=JCPCDT&rft_id=info:doi/10.1097/00005344-199401000-00023&rft_dat=%3Cproquest_cross%3E76420453%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76420453&rft_id=info:pmid/7511730&rfr_iscdi=true |